Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
CAS NO.104987-11-3
Preview |
|
Tacrolimus Basic information |
Product Name: | Tacrolimus |
Synonyms: | (2-propenyl)-,(3s-(3r*(e(1s*,3s*,4s*)),4s*,5r*,8s*,9e,12r*,14r*,15s*,16r*,18s*;,19s*,26ar*))-;16-dimethoxy-4,10,12,18-tetramethyl-8-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1;19-epoxy-3h-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4h,23h)-tetrone,5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-14,16-dim;6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-5;fr900506;prograf;tsukubaenolide |
CAS: | 104987-11-3 |
MF: | C44H69NO12 |
MW: | 804.02 |
EINECS: | |
Product Categories: | Active Pharmaceutical Ingredients;Immunosuppressant.;Intermediates & Fine Chemicals;Pharmaceuticals;API;Chiral Reagents;Fujimycin, Prograf;antibiotic;Inhibitors |
Mol File: | 104987-11-3.mol |
Tacrolimus Chemical Properties |
mp | 113-115°C |
storage temp. | −20°C |
solubility | DMSO: >3 mg/mL |
form | solid |
color | white |
CAS DataBase Reference | 104987-11-3(CAS DataBase Reference) |
Safety Information |
Hazard Codes | T,Xi,Xn,F |
Risk Statements | 25-36/37/38-36-20/21/22-11 |
Safety Statements | 45-36-26-36/37-16 |
RIDADR | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | KD4201200 |
Tacrolimus Usage And Synthesis |
Chemical Properties | White Crystalline Solid |
Usage | An immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2. Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release. |
Usage | FK-506 (Tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system |
Usage | Tacrolimus (fujimycin) was discovered as a potent inhibitor of IL2 production in a targeted search for novel immunosuppressants. Tacrolimus acts by blocking T cell proliferation in vitro by inhibiting the generation of several lymphokines, notably the original target IL-2. Tacrolimus inhibits the activity of FK-506 binding protein, Ca2+-dependent phosphatase and calcineurin, and activates NF-κB through phosphorylation and degradation of IκBα. |
Usage | treatment of Cushing's syndrome |
Usage | For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, |
Tacrolimus Preparation Products And Raw materials |
Raw materials | Ethyl acetate-->Celite -->Starch-->Yeast extract-->Active Calcium |